Many individuals with chronic obstructive pulmonary disease describe exacerbations in personal, varied terms, revealing a ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Upstream Bio has dosed the first subject in the Phase II trial of verekitug in individuals with chronic obstructive pulmonary disease (COPD).

Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...

Patients with bronchiectasis face heightened risks of severe exacerbation and mortality after COVID-19 recovery, especially ...

Dietary approaches are shaping up as a key aspect of chronic obstructive pulmonary disease (COPD) management.

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

Researchers have found that changes in speech recorded using a smartphone can be used to predict when a patient with chronic obstructive pulmonary disease (COPD) is at risk of an exacerbation ...

A recent national study revealed ongoing symptom burden and communication gaps in COPD care, and provided physicians with actionable improvement strategies.